Carnosine Cancer Research Results

Carno, Carnosine: Click to Expand ⟱
Features:

Carnosine (CAR; β-alanyl-L-histidine) is an endogenous dipeptide and dietary supplement (high in meat; also synthesized).
Primary mechanisms (conceptual rank):
1) Carbonyl/aldehyde scavenging + anti-glycation (AGE) suppression → proteostasis stress ↓ (P/R)
2) Cancer metabolism interference (Warburg/glycolysis pressure) → proliferation ↓ (model-dependent; often high concentration) (R/G)
3) Metal chelation + ROS/RNS buffering (secondary redox modulation) (P/R; context-dependent)
Bioavailability / PK: Orally absorbed, but rapidly hydrolyzed in human blood by carnosinase (CN1) → very short circulating half-life; sustained systemic CAR exposure is limited vs β-alanine/histidine metabolites.
In-vitro vs realistic exposure: Many anti-proliferative / glycolysis effects are reported at high µM–mM CAR in vitro, commonly exceeding realistic systemic CAR exposure due to rapid serum hydrolysis.
Clinical evidence status (cancer): Predominantly preclinical for direct anti-cancer effects; human oncology evidence is mainly adjunct/supportive (e.g., zinc-L-carnosine for radiation-related symptoms), not established as an anti-tumor monotherapy.

L-Carnosine (usually just called "Carnosine") is a naturally occurring dipeptide composed of L-histidine and β-alanine, found in high concentrations in muscle and brain tissue.
-Source: only found in animals Beef(372mg/100g), ChickenBreast(290mg/100g), Pork(276mg/100g), TurkeyBreast(240mg/100g)
-Anserine is a derivative of carnosine
-Scavenges reactive oxygen species (ROS)
-Inhibits formation of AGEs (advanced glycation end-products), which are linked to aging and neurodegeneration.
-Metal chelator: Binds excess zinc, copper, and iron—important in brain health.


Carnosine (CAR) — Pathway / Axis Effects (Cancer vs Normal)

Rank Pathway / Axis Cancer Cells (↑ / ↓ / ↔) Normal Cells (↑ / ↓ / ↔) TSF Primary Effect Notes / Interpretation
1 Carbonyl stress / anti-glycation (AGE) ↓ proteotoxic/carbonyl stress (context-dependent) ↓ glycation damage (protective) P/R Cell stress buffering Core “chemoprotective” chemistry: nucleophilic scavenging of reactive carbonyls; cancer-direction depends on whether tumor relies on carbonyl-stress adaptation.
2 Warburg / glycolysis pressure ↓ glycolysis flux (model-dependent; high concentration only) ↔ R/G Anti-proliferative (subset) Frequently reported in vitro with supraphysiologic CAR; translation constrained by rapid serum hydrolysis in humans.
3 Mitochondrial function / energetic stress ↔ / ↑ energetic stress (model-dependent) ↔ / protective (context-dependent) R Growth suppression vs resilience Direction varies by baseline metabolic state and substrate availability; often secondary to carbonyl/redox effects.
4 ROS ↓ ROS (secondary; context-dependent) ↓ oxidative damage (protective) P/R Redox buffering Typically described as antioxidant buffering; paradoxical “ROS ↑” cytotoxicity is not a dominant CAR narrative.
5 NRF2 (stress-response axis) ↔ / ↑ cytoprotection (context-dependent; resistance risk) ↔ / ↑ protective G Adaptive stress signaling If NRF2 is already oncogenic (e.g., KEAP1/NFE2L2-altered tumors), further cytoprotection could be undesirable.
6 Ca²⁺ (ER/mitochondria stress coupling) ↔ (not primary; model-dependent) ↔ R Stress modulation (secondary) Include only as a secondary axis: CAR’s dominant reported levers are carbonyl/redox/metabolic rather than direct Ca²⁺ channel control.
7 Ferroptosis ↔ (context-dependent) ↔ R/G Unclear / secondary CAR’s anti-lipid-peroxidation tendency could oppose ferroptosis in some contexts; evidence is not central vs carbonyl/AGE chemistry.
8 Clinical Translation Constraint Human systemic CAR exposure is constrained by rapid serum hydrolysis (CN1); much in-vitro anti-cancer work uses high µM–mM. Strongest human oncology signal is adjunct/supportive use (e.g., zinc-L-carnosine symptom prevention), not proven tumor regression. — PK-limited; adjunct-only Consider delivery strategies/analogs (e.g., carnosinase-resistant histidine dipeptides) if pursuing systemic pharmacology.

TSF legend: P: 0–30 min (primary/rapid effects; direct enzyme/redox interactions) · R: 30 min–3 hr (acute signaling + stress responses) · G: >3 hr (gene-regulatory adaptation; phenotype outcomes)
Scientific Papers found: Click to Expand⟱
3869- Carno,    Carnosine, Small but Mighty—Prospect of Use as Functional Ingredient for Functional Food Formulation
- Review, AD, NA - Review, Stroke, NA
"highlight2" >*ROS↓, "highlight2" >*IronCh↑, "highlight2" >*AntiAge↑, "highlight2" >*antiOx↑, "highlight2" >*Inflam↓, "highlight2" >*neuroP↑, "highlight2" >*lipid-P↓, "highlight2" >*toxicity↓, "highlight2" >*NOX4↓, "highlight2" >*SOD↑, "highlight2" >*HNE↓, "highlight2" >*IL6↓, "highlight2" >*TNF-α↓, "highlight2" >*IL1β↓, "highlight2" >*Sepsis↓, "highlight2" >*eff↑, "highlight2" >*GABA↝, "highlight2" >*Aβ↓, "highlight2" >Glycolysis↓, "highlight2" >AntiTum↑, "highlight2" >p‑Akt↓, "highlight2" >TumCCA↑, "highlight2" >angioG↓, "highlight2" >VEGFR2↓, "highlight2" >NF-kB↓,
3870- Carno,    Could carnosine or related structures suppress Alzheimer's disease?
- Review, AD, NA
"highlight2" >*IronCh↑, "highlight2" >*Aβ↓, "highlight2" >*ROS↓, "highlight2" >*Vim↓,
3871- Carno,    Unveiling the Hidden Therapeutic Potential of Carnosine, a Molecule with a Multimodal Mechanism of Action: A Position Paper
- Review, NA, NA
"highlight2" >*ROS↓, "highlight2" >*NO↓, "highlight2" >*Inflam↓,
3872- Carno,    Carnosine Protects Macrophages against the Toxicity of Aβ1-42 Oligomers by Decreasing Oxidative Stress
- in-vitro, AD, NA
"highlight2" >*antiOx↑, "highlight2" >*Inflam↓, "highlight2" >*Aβ↓, "highlight2" >*neuroP↑, "highlight2" >*ROS↓, "highlight2" >*NO↓,
3873- Carno,    Effects of dietary supplementation of carnosine on mitochondrial dysfunction, amyloid pathology, and cognitive deficits in 3xTg-AD mice
- in-vivo, AD, NA
"highlight2" >*ROS↓, "highlight2" >*IronCh↑, "highlight2" >*Aβ↓, "highlight2" >*AntiAge↑, "highlight2" >*lipid-P↓, "highlight2" >*cognitive↑, "highlight2" >*memory∅,
3874- Carno,    Effects of zinc and carnosine on aggregation kinetics of Amyloid-β40 peptide
- Review, AD, NA
"highlight2" >*Aβ↓, "highlight2" >*IronCh↑,
3875- Carno,    Ionophore Ability of Carnosine and Its Trehalose Conjugate Assists Copper Signal in Triggering Brain-Derived Neurotrophic Factor and Vascular Endothelial Growth Factor Activation In Vitro
- in-vitro, AD, NA
"highlight2" >*IronCh↑, "highlight2" >*CREB↑, "highlight2" >*BDNF↑, "highlight2" >*NGF↑, "highlight2" >*antiOx↑, "highlight2" >*ROS↓,
3876- Carno,  Ex,    Swimming exercise versus L-carnosine supplementation for Alzheimer’s dementia in rats: implication of circulating and hippocampal FNDC5/irisin
- in-vivo, AD, NA
"highlight2" >*cognitive↑, "highlight2" >*neuroP↑,
3877- Carno,    Carnosine, diabetes and Alzheimer's disease
- Review, AD, NA
"highlight2" >*toxicity∅, "highlight2" >*antiOx↑, "highlight2" >IronCh↑,
3878- Carno,    Safety and Efficacy Evaluation of Carnosine, An Endogenous Neuroprotective Agent for Ischemic Stroke
- in-vivo, Stroke, NA
"highlight2" >*toxicity∅, "highlight2" >*antiOx↑, "highlight2" >*neuroP↑, "highlight2" >*IronCh↑, "highlight2" >*ROS↓,
3879- Carno,    Daily Carnosine and Anserine Supplementation Alters Verbal Episodic Memory and Resting State Network Connectivity in Healthy Elderly Adults
- Human, AD, NA
"highlight2" >*memory↑, "highlight2" >*cognitive↑,
3880- Carno,    EFFECT OF ANSERINE/CARNOSINE SUPPLEMENTATION ON THE PREVENTION OF ALZHEIMER'S DISEASE IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT
- Trial, AD, NA
"highlight2" >*cognitive↑, "highlight2" >*other↑,
3881- Carno,    The Therapeutic Potential of Carnosine/Anserine Supplementation against Cognitive Decline: A Systematic Review with Meta-Analysis
- Review, AD, NA
"highlight2" >*cognitive↑,

Showing Research Papers: 1 to 13 of 13

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 13

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 5,   HNE↓, 1,   lipid-P↓, 2,   NOX4↓, 1,   ROS↓, 7,   SOD↑, 1,  

Metal & Cofactor Biology ⓘ

IronCh↑, 6,  

Core Metabolism/Glycolysis ⓘ

CREB↑, 1,  

Transcription & Epigenetics ⓘ

other↑, 1,  

Migration ⓘ

Vim↓, 1,  

Angiogenesis & Vasculature ⓘ

NO↓, 2,  

Immune & Inflammatory Signaling ⓘ

IL1β↓, 1,   IL6↓, 1,   Inflam↓, 3,   TNF-α↓, 1,  

Synaptic & Neurotransmission ⓘ

BDNF↑, 1,   GABA↝, 1,   NGF↑, 1,  

Protein Aggregation ⓘ

Aβ↓, 5,  

Drug Metabolism & Resistance ⓘ

eff↑, 1,  

Clinical Biomarkers ⓘ

IL6↓, 1,  

Functional Outcomes ⓘ

AntiAge↑, 2,   cognitive↑, 5,   memory↑, 1,   memory∅, 1,   neuroP↑, 4,   toxicity↓, 1,   toxicity∅, 2,  

Infection & Microbiome ⓘ

Sepsis↓, 1,  
Total Targets: 29

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:351  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page